Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis

Company Overview

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Key Stats

• Today's Range: $8.42 to $8.99
• 50-Day Range: $6.12 to $9.86
• 52-Week Range: $5.01 to $54.95
• Volume: 3,067 shs
• Average Volume: 137,282 shs
• Market Capitalization: $5.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Quoin Pharmaceuticals Stock Analysis - MarketRank™

Quoin Pharmaceuticals scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Quoin Pharmaceuticals.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Quoin Pharmaceuticals are expected to grow in the coming year, from ($2.05) to ($2.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Quoin Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quoin Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Quoin Pharmaceuticals has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.77% of the float of Quoin Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Quoin Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quoin Pharmaceuticals has recently decreased by 71.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quoin Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Quoin Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.77% of the float of Quoin Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Quoin Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quoin Pharmaceuticals has recently decreased by 71.18%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for QNRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Quoin Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.70% of the stock of Quoin Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 8.63% of the stock of Quoin Pharmaceuticals is held by institutions.

QNRX Stock Analysis - Frequently Asked Questions

How have QNRX shares performed this year?

Quoin Pharmaceuticals' stock was trading at $22.7745 on January 1st, 2025. Since then, QNRX shares have decreased by 62.8% and is now trading at $8.48.

How were Quoin Pharmaceuticals' earnings last quarter?

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) announced its earnings results on Tuesday, May, 13th. The company reported ($6.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.85) by $2.65.

When did Quoin Pharmaceuticals' stock split?

Quoin Pharmaceuticals shares reverse split before market open on Monday, July 17th 2023.The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Quoin Pharmaceuticals?

Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Quoin Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Quoin Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Zomedica (ZOM) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:QNRX
• CIK: 1671502
• Web: quoinpharma.com
• Phone: (703) 980-4182
• Fax: 972-9767-8750
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($48.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.96 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -148.97%
• Return on Assets: -77.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.57
• Quick Ratio: 2.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $35.47 per share
• Price / Book: 0.24

Miscellaneous

• Outstanding Shares: 590,000
• Free Float: 566,000
• Market Cap: $5.00 million
• Optionable: Not Optionable
• Beta: 1.47